HGS ($HGSI) making Benlysta 24/7 in prep for launch

Human Genome Sciences ($HGSI) has been steadily ramping up its manufacturing ops for Benlysta this year. And now that it's breezed past its expert panel review with a big vote in the lupus drug's favor, HGS says that it's working around the clock to produce more in anticipation of an approval. The FDA has a December 9 deadline for making a decision on the drug, but nothing is guaranteed and some analysts have speculated that questions about labeling could force the agency to take more time before it offers a green light on HGS's first market launch. Report

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.